Drugs / XAB05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05307406 | Jan → May 2022 | bacterial infectious disease | Xenothera SAS | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XAB05 | “A First-in-Human Study With XAB05 in Healthy Subjects” NCT05307406 ↗ |
| Route | Intravenous | “Single ascending dose from 0.25 mg/kg up to 20mg/kg IV infusion” NCT05307406 ↗ |